Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 31

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Tezepelumab on Airway Inflammation in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Region Hovedstaden

Respiratory tract infection viral

Recruiting

Study on Stopping Antibiotics in Adults with Viral Respiratory Infections Using Tetracyclines and Other Antibiotics

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Sponsor:Akershus University Hospital

Pulmonary sarcoidosis

Recruiting

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Oslo University Hospital HF

Interstitial lung disease

Recruiting

Study to evaluate oxygen therapy effects on physical activity in patients with fibrotic interstitial lung disease who experience low oxygen levels during exercise

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Oxygen
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Pulmonary embolism

Recruiting

Study on the Effectiveness of Oxygen for Patients with Intermediate-Risk Acute Pulmonary Embolism

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Non-small cell lung cancer+1

Recruiting

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Acute respiratory distress syndrome

Recruiting

Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Gastrointestinal carcinoma+1

Recruiting

Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1084
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+3

Recruiting

Study on Durvalumab with Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Amsterdam UMC Stichting

Asthma

Recruiting

Study on Glycopyrronium Bromide for Children Aged 6-12 with Asthma

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Salbutamol
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.